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Summary The multivariate lognormal survival model can be used to determine the relationship of prognostic
covariates to two important parameters of malignancy. Cured fraction and median survival time among
uncured patients. Analysis with this model revealed that cured fraction is primarily a function of histologic
type and node status, while median survival time is primarily a function of age and node status. Patient sex
was also related to likelihood of cure, but this association was of marginal significance. The symmetric impact
of node status on both cured fraction and median survival time is consistent with known biologic principles.
The strongly asymmetric relationships of histologic grade to cured fraction and age to survival time suggest,
however, that likelihood of cure and survival time may not operate by identical biologic mechanisms.
A variety of statistical models are now available for assessing
survival. In order to select the appropriate model for a
particular analysis, it is important to consider the time-course
of the hazard under study. For example, to model the risk of
developing cancer in humans or in experimental animals
exposed to a carcinogen, one must select a hazard function
(such as the Weibul or Gompertz) that increases over time,
to match the progressive risk that is observed in these
populations (Cook et al., 1969; Pike 1966). A progressive
increase in risk is also required to model deaths from all
causes among adult humans, since likelihood of death inc-
reases with age in this population.
An altogether different model is needed, however, when
studying survival with respect to a specific histologic type of
tumour that has been treated by a potentially curative
therapy. In order to focus on the tumour under study, dis-
tinction must be made between deaths due to this tumour
and deaths due to unrelated causes. If reliable follow-up data
is available, one can consider patients that died of other
causes to be withdrawn alive at the time of death (Cutler &
Axtell, 1969). Since risk of death from the tumour under
study may eventually decline, as ascending hazard function
would not give a good fit to observed survival (Figure 1).
Furthermore, those patients that are cured are not at risk of
death from their tumour, and thus a successful model must
allow for a risk-free portion (or cured fraction) within the
population.
This reasoning suggests that a model of tumour-specific
survival can be constructed by combining a cured fraction
with a distribution of time-to-death among uncured patients.
One alternative is to approximate specific biologic pathways
within the malignant process, using selected mathematical
functions. Though this approach has become popular with
the advent of sophisticated computer technology, it may
demand numerous simplifying assumptions and the resulting
conclusions, though sometimes useful, may apply only to the
malignancy for which the model was derived (Birkhead,
1985; Gregory et al., 1991). A more direct approach, and one
with a long history, is the lognormal survival model.
Originally present by Boag in 1949, this model used the
lognormal function to approximate the distribution of time
to death from tumour (Boag, 1949). The lognormal function
has been shown to provide a good fit to clinical data for
a variety of cancers, including those of breast, cervix, eye,
and head and neck (Mould & Boag, 1975; Mould et al.,
1976; Rutqvist et al., 1984; Gamel et al., 1990). Because this
model provides estimates of essential survival parameters
(i.e., cured fraction [C], mean log survival time [M] and
standard deviation survival time [S]), it enjoys an obvious
advantage over models that are non-parametric with respect
to time, such as the Cox regression (Cox, 1972).
Despite this advantage, the original model of Boag suffers
a major deficiency: it does not allow for variations in cured
fraction and mean log survival time among members of the
study population. Thus to examine the impact of patient age
or tumour stage, for example, one must subdivide the
population into multiple subgroups and derive separate
estimate of C and M for each group. Subdividing patients in
this fashion reduces statistical power, especially if an attempt
is made to determine simultaneously the impacts of multiple
prognostic covariates.
Recently, a refinement of the original Boag model has been
developed that allows C and M to be expressed as linear
regressions on prognostic covariates (Gamel et al., 1990), As
a result of this refinement, cured fraction and mean log
survival time can be allowed to vary from patient to patient,
depending on such factors as age and sex of the patient, and
stage and histologic characteristics of the tumour.
We will report on the results from this method when
applied to data from 2,073 cases of squamous cell carcinoma
of the head and neck.
Methods
Patients studied
Since 1963 it has been the policy of the Department of
Otorhinolaryngology at the University of Liverpool to store
in a prospective manner the data on all patients with head
and neck tumours. This data base now includes 3,285 cases
of histologically proven squamous carcinoma of the head and
neck. Updating is performed at every patient episode, and
cause of death is determined from personal records or from
the Mersey Regional Cancer Registry. Each month a pro-
gram is run to identify records with incomplete data.
Computerised records were reviewed for all patients seen
at the Royal Liverpool Hospital between January 1963 and
October 1991 with the diagnosis of squamous carcinoma of
the head and neck. Of these, a total of 649 were omitted for
one or more of the following reasons: last status was not
known (37), degree of the histologic differentiation was not
known (508), or node status was not known (104). For each
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Figure 1 The symbols represent actuarial tumour-related survival for the 2073 patients included in this analysis. The continuous
line represents the multivariate lognormal survival model derived from this data set.
of the remaining 2,073 patients, the following covariates were
known: sex of the patient, age of the patient at the time of
initial treatment, degree of differentiation of the primary
tumour, node status at the time of treatment, duration of
followup, and status at last followup.
Host factors are shown in Table I and tumour factors are
shown in Table II. The patient's performance status was
classified by the Eastern Cooperative Oncology Group
Method (A.J.C. Manual for staging of cancer, 1988). Both
Primary tumour and neck node metastases (if any), were
classified by the UICC method (UICC International Union
Against Cancer, 1987). Where a resection was carried out,
the specimen was examined macroscopically by a pathologist
and then microscopically by a histologist and assigned an
appropriate pT stage. Histologic grade was assessed accord-
ing to the method generally used in the UK (Broders, 1926;
Thomson, 1939) and assigned the category of well,
moderately, or poorly differentiated.
In Table III, primary sites for the data base are given.
Approximately one-third of the cases are carcinoma of the
larnyx and a further third are carcinoma of the pharynx.
One-fifth of cases has a carcinoma of the oral cavity.
Tumours of the nose and sinuses, post-nasal space, ear,
salivary glands, etc. form the remaining cases.
In Table IV the various forms of treatment are indicated.
In the UK, the general policy of the Head and Neck Cancer
Units is to treat by primary radiotherapy wherever possible,
with the option of salvage surgery. In the present data base,
51% of all new patients were treated initially by radiotherapy
with curative intent, but approximately one-third of these
patients required salvage surgery. Of all patients, 29% were
Table H Patients: tumour factors
Histology
T Stage
Table I Patients: host factors
Age Male 61.8 years
Female 62.1 years
Sex Male 70%
Female 30%
Total 100%
Performance status
0 50%
I 16%
II 5%
III 1%
IV 2%
Previous treatment elsewhere 23%
Not recorded 3%
Total 100%
N Stage
Well differentiated
Moderately well differentiated
Poorly differentiated
Not classified
Total
T,
T2
T3
T4
Previously treated elsewhere
Not classified
Total
No
N,
N2a
N2b
N2c
N3
Previously treated elsewhere
Not classified
Total
31%
26%
21%
22%
100%
28%
16%
21%
11%
23%
1%
100%
49%
10%
5%
1%
4%
6%
23%
2%
100%
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Table III Sites
Larnyx 37%
Oral cavity 21%
Hypopharynx 18%
Oropharynx 14%
Nose and sinuses 4%
Post nasal space 2%
Ear 2%
Other 2%
Total 100%
Table IV Treatment
Radiotherapy 51%
Surgery 29%
No treatment 17%
Other 3%
Total 100%
treated initially by surgery with curative intent, while 17% of
all patients were unsuitable for any form of treatment. A
small proportion of patients required treatment with
chemotherapy or other palliative measures.
Sex was coded as 1 for male and 2 for female. Age at the
time of initial treatment was coded in years. Preliminary
studies of degree of histologic differentiation revealed that
the increment between well and moderately differentiated
tumours had an impact similar to the increment between
moderately and poorly differentiated tumours. Thus degree
of differentiation was coded as 1 for well, 2 for moderately,
and 3 for poorly differentiated. Node status was initially
coded as 1 if no lymph nodes were found to be involved and
as 2 if one or more nodes were found to be involved at the
time of initial treatment. Further analysis using the
univariate lognormal model demonstrated a substantially bet-
ter fit to observed survival data (using the criterion of log
likelihood function) if node status was coded simply as the
number of positive nodes (range, 0-7), and thus this second
untransformed value was adopted for survival analysis.
Data analysis
The univariate and multivariate lognormal models have been
described in detail elsewhere (Boag, 1949; Gamel et al.,
1990). For univariate analysis, each covariate was entered
into both components of the lognormal model (i.e., cured
fraction and mean log survival time). For multivariate
analysis, all covariates were included in both components of
the lognormal model. In order to demonstrate the relative
prognostic value of all covariates, no step-down procedure
was performed.
To determine the interaction of covariates, standard linear
regression analysis was used. In order to assess the possible
interaction of the studied covariates with therapeutic
decisions, cross-correlation with type of therapy was also
examined. For this analysis, surgery was coded as 2 if
definitive resection was attempted and as 1 if there was no
surgical intervention other than biopsy or palliative proce-
dures. Radiation was coded as 1 if no radiation was given
and as 2 if therapeutic (excluding palliative) radiation was
performed.
Results
Of the 2,073 cases included in survival analysis, 928 were
coded as dead of their tumour at last followup, 500 were
coded as dead of other causes, and 645 were coded as
withdrawn alive. For those dead of their tumour, range of
followup was 1 day to 13.0 years, with a median of 0.85
years, a mean of 1.30 years, and a standard deviation of 1.58
years. For those dead of other causes, the corresponding
values were 4 days to 18.8 years, 2.159 years, 3.47 years, and
3.68 years respectively. For those withdrawn alive, the corres-
ponding values were 1 day to 24.0 years, 5.64 years, 6.154
years, and 4.51 years respectively.
The results of univariate and multivariate lognormal
analysis are shown in Table V. Cross-correlation among
covariates is shown in Table VI. The clinical impact of
covariates is demonstrated in Table VII.
Discussion
Norris found that the most important predictor of survival in
laryngeal cancer was the presence or absence of lymph node
metastases (Norris, 1963). Stell noted that neck node status
completely overshadows other prognostic factors in laryngeal
carcinoma and that patients with nodal involvement were
likely to have high T stage and poorly differentiated tumours
(Stell, 1990b). Furthermore, he found that pathological N
stage and the presence or absence of capsular rupture were of
paramount prognostic importance.
Given the well-established predictive value of nodal status
for patients with squamous carcinoma of the head and neck
Table VI Cross-correlation among covariates for 2,073 patients
with squamous cell carcinoma of the head and neck
Correlation Coefficient (r)a
Hist. Node
Covariate Age Sex grade status
Hist. Grade -0.03 +0.05
Node Status -0.08 -0.05 +0.12
Surgery -0.12 +0.02 +0.01 -0.01
Radiation -0.04 -0.02 -0.02 -0.28
aFor r >0.04, P<0.05; for r >0.06, P<0.005; for r >
0.075,P<0.0001.
Table V Maximum-likelihood estimates of coefficients of lognormal
model
Covariate Univariate analysis Multivariate analysis
(Parameter) Constant Covar. SE t-valuea Constant Covar. SE t-valuea
(Cured fraction)
Sex -0.112 -0.231 0.139 1.663 1.903 -0.336 0.154 2.175
Age 0.064 -0.007 0.006 1.287 - -0.012 0.006 1.844
Hist. Gr. 0.398 -0.454 0.087 5.215 -0.434 0.097 4.463
Node St. -0.067 -0.510 0.080 6.332 - -0.565 0.104 5.411
(Mean log survival time)
Sex 0.241 -0.086 0.122 0.707 2.378 -0.092 0.114 0.811
Age 1.830 -0.027 0.005 5.611 - -0.032 0.005 6.740
Hist. Gr. 0.101 0.022 0.072 0.303 0.072 0.067 1.073
Node St. 0.389 -0.175 0.025 7.107 -0.182 0.024 7.554
adf = xo; t = 1.692 and t = 2.81 correspond to P-values of 0.05 and
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Table VII Clinical impact of covariates estimated by multivariate
lognormal modela
Number Median
Hist. positive Cured survival
Sex Age (Yrs) grade nodes fraction time (yrs)
Female 30 Well 0 0.685 4.09
Male 30 Well 0 0.608 _b
Female 60 Well 0 _b 1.58
Female 30 Poorly 0 0.477 _b
Female 30 Well 1 0.552 3.41
Female 30 Well 3 0.285 2.37
aFirst row represents baseline values; each other row has only one
covariate changed from baseline.
bIn the multivariate lognormal model, the changed covariate was not
statistically significant in its association with this parameter.
(SCHN), it is not surprising to find that this variable is
highly associated with both cured fraction and survival time.
The biologic principles underlying this association are appar-
ent: likelihood of cure is significantly diminished by the
dissemination of tumour to adjacent or regional lymph
nodes, while the dissemination of tumour cells to lymph
nodes by the time of initial evaluation can be expected to
shorten the time between initial evaluation and death from
tumour.
As can be seen in Table V, histologic type and age are also
important predictors for SCHN. Unlike nodal status, how-
ever, these two covariates are asymmetric predictors- his-
tologic type is significantly associated only with cured frac-
tion, while age is significantly associated only with median
survival time.
Kleinsasser in 1961 noted that undifferentiated carcinoma
of the larnyx has a poor prognosis and this association was
attributed to the fact that these tumours metastasise early.
Stell, however, (Stell, 1990b) found histological differentiation
to be nonsignificant regarding survival after allowing for
confounding variables. Our finding that histologic type is
associated with cured fraction rather than survival time may
explain this apparent contradiction.
The existence of highly asymmetric predictors such as age
and histologic type suggest an important conclusion-that
those mechanisms which govern the likelihood of metastasis
are distinct from those that govern survival time for uncured
patients. Specifically, poorly differentiated cells within SCHN
are apparently more likely to metastasise than well
differentiated cells, but these metastatic foci do not seem to
grow more quickly than their better differentiated counter-
parts. On the other hand, old age has a highly significant
interaction with survival time but not with cured fraction,
suggesting the possibility that rate ofmetastatic proliferation,
rather than the occurrence of metastasis, increases substan-
tially with increasing age at diagnosis. A second possibility is
age-associated delay in diagnosis; this association appears
unlikely, however, since the multivariate model contains a
covariate (node status) that characterises tumour stage at
diagnosis and thus should control for delay in diagnosis. A
third possibility is that older patients succumb at a relatively
smaller tumour burden than younger patients. It should be
noted that age also demonstrated a strong and asymmetric
association with survival time for patients with melanoma of
the skin and of the eye (Gamel et al., in preparation a,b).
For many years it has been assumed that prognosis from
SCHN is better in younger than older patients (Lauerma,
1967). This assumption has been borne out by careful statis-
tical investigations (Huygen et al., 1980; Katz, 1983). On the
other hand, with use of the Cox regression model Stell found
that age was not a significant predictor of survival when
allowance was made for those patients that were untreated or
died of intercurrent disease or of a second primary tumour
(Stell, 1990a). This disparity may result from a difference in
statistical methods.
Before attributing biologic significance to these observa-
tions, however, it is important to consider the interactions
among covariates shown in Table VI. These interactions
imply that patients with nodal involvement are less likely to
have radiation therapy and more likely to have poorly
differentiated tumours than those without nodal involvement.
Old patients are also less likely than young patients to have
surgery and less likely to have nodal involvement. Some of
these associations are of marginal biologic significance-e.g.,
only 0.64% of the variation in age can be explained by node
status.
Nevertheless, because of the large number of patients
included in this study, there may be sufficient statistical
significance to impact patient survival. Thus the interaction
of covariates with therapy and with each other can
significantly affect their prognostic value within the lognor-
mal model.
Because of these limitations, are because of the limitations
that arise from the complexities of multivariate survival
analysis itself, no firm conclusions can be drawn from the
results shown in Table V. Nevertheless, these findings raise
important biologic questions that warrant further investiga-
tion, both in the clinic and in the laboratory.
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